Details of the Drug Reposition

General Information of This Drug (ID: DMIEU69)

Drug Name
Salmeterol   DMIEU69
Synonyms
Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
Therapeutic Class
Bronchodilator Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Intrinsic asthma DIS2U1Q9 N.A. Approved [1]
Pulmonary emphysema DIS5M7HZ CA21.Z Approved [1]
Allergic asthma DISHF0H3 CA23.0 Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic obstructive pulmonary disease DISQCIRF CA22 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Salmeterol FDA Label
2 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors